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Summary
 
Neovascularization is essential for growth and spread of primary and metastatic tumors. We
have identified a novel cytokine, endothelial-monocyte activating polypeptide (EMAP) II, that
potently inhibits tumor growth, and appears to have antiangiogenic activity. Mice implanted
with Matrigel showed an intense local angiogenic response, which EMAP II blocked by 76%
 
(
 
P
 
 , 
 
0.001). Neovascularization of the mouse cornea was similarly prevented by EMAP II (
 
P
 
 ,
 
0.003). Intraperitoneally administered EMAP II suppressed the growth of primary Lewis lung
carcinomas, with a reduction in tumor volume of 65% versus controls (
 
P
 
 , 
 
0.003). Tumors from
human breast carcinoma–derived MDA-MB 468 cells were suppressed by 
 
.
 
80% in EMAP II–
treated animals (
 
P
 
 , 
 
0.005). In a lung metastasis model, EMAP II blocked outgrowth of Lewis
lung carcinoma macrometastases; total surface metastases were diminished by 65%, and of the 35%
 
metastases present, 
 
ø
 
80% were inhibited with maximum diameter 
 
,
 
2 mm (
 
P
 
 , 
 
0.002 vs. con-
trols). In growing capillary endothelial cultures, EMAP II induced apoptosis in a time- and dose-
dependent manner, whereas other cell types were unaffected. These data suggest that EMAP II
is a tumor-suppressive mediator with antiangiogenic properties allowing it to target growing
endothelium and limit establishment of neovasculature.
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blood vessels
 
M
 
urine methylcholanthrene A–induced (meth A)
 
1
 
 fi-
brosarcomas, which exhibit spontaneous vascular in-
sufficiency manifested by a heterogeneous pattern of throm-
bohemorrhage and central necrosis, as well as a failure to
form metastatic lesions (1, 2), provide an ideal starting
point for isolation of tumor-derived mediators that perturb
the vasculature (3–6). We purified a novel cytokine-like
molecule, endothelial-monocyte activating polypeptide
(EMAP) II, from meth A–conditioned medium based on
its capacity to induce activation of endothelial cells (ECs)
and mononuclear phagocytes (5, 6). This single chain
polypeptide, devoid of a signal sequence, is initially syn-
 
thesized as an 
 
ø
 
34-kD intracellular precursor, which is
processed to the mature 
 
ø
 
20-kD form and released extra-
cellularly by an as yet unidentified pathway. EMAP II
showed no significant homology to other known proteins
such as cytokines or growth factors. However, an aspartic
acid residue is present in the P-1 position in both murine
and human EMAP II, suggesting that a cysteine protease in
the IL-1
 
b
 
–converting enzyme family might be responsible
for producing mature EMAP II from its pro-form. Our ini-
 
1
 
Abbreviations used in this paper:
 
 bFGF, basic fibroblast growth factor; BrdU,
5-bromodeoxyuridine; DAP-1, 6-diamidino-2-phenylindoledilactate; EC,
endothelial cell; EMAP, endothelial-monocyte activating polypeptide;
LLC, Lewis lung carcinoma; meth A, methylcholanthrene A–induced fi-
brosarcoma; RT, reverse transcription; SMC, smooth muscle cell;
TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP-biotin
nick end labeling; VEGF, vascular endothelial growth factor. 
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Antiangiogenesis and EMAP II
 
tial characterization of EMAP II suggested that its proper-
ties resembled those of proinflammatory mediators. For
example, EMAP II induced endothelial release of von Wille-
brand factor, translocation of P-selectin to the cell surface,
and synthesis and expression of E-selectin and procoagulant
tissue factor (5, 6); these, and EMAP II–mediated activa-
tion of cultured monocytes, resulting in production of cyto-
kines and stimulation of cell migration, suggested phlogo-
genic properties. However, EMAP II administered in
vivo, locally or systemically, gave rise to, at most, mild and
transient inflammation (6), suggesting that its effects were
quite different from those of TNF or IL-1 (2, 7, 8).
In this study we report that EMAP II has antiangiogenic
properties preventing blood vessel ingrowth in two experi-
mental angiogenesis models, and suppressing the growth of
primary and metastatic tumors without toxicity in normal
organs. Consistent with this hypothesis, EMAP II appears
to target growing ECs; exposure of growing cultured capil-
lary endothelium to EMAP II induces apoptosis, which is
magnified by concomitant hypoxia. These data suggest that
EMAP II is a polypeptide with antiangiogenic properties
that targets rapidly growing vascular beds.
 
Materials and Methods
 
Cell Culture and In Vitro Assays.
 
Bovine aortic and capillary
ECs were isolated from calf aortae and adrenal glands, respectively,
grown in culture, and characterized based on the presence of
vonWillebrand factor and thrombomodulin, as described previ-
ously (9). Human umbilical vein ECs (ECV-304 from American
Type Culture Collection) were grown in DMEM containing
FBS (10%). Bovine vascular smooth muscle cells (SMCs) were
prepared by additional scraping of the aortae after removal of the
endothelium, and were characterized based on the presence of
SMC actin (10). Lewis lung carcinoma (LLC) cells were ob-
tained from American Type Culture Collection and maintained in
high glucose DMEM (GIBCO BRL) containing FBS (10%).
MDA-MB 468 cells, derived from an estrogen-independent breast
carcinoma
 
 
 
(HTB 132), were obtained from American Type Cul-
ture Collection. EMAP II–induced apoptosis was studied in sub-
confluent endothelial cultures (9) using the 5-bromodeoxyuri-
dine (BrdU) incorporation kit from Boehringer Mannheim
according to the manufacturer’s instructions. In brief, cells were
incubated for 12 h with BrdU, plated for 24 h on 96-well plates,
then treated with either vehicle (FBS, 10%) alone or vehicle plus
recombinant (r)EMAP II, as indicated. After 12 or 24 h at 37
 
8
 
C,
cells were lysed, centrifuged (250 
 
g
 
) for 10 min, and the top 0.1 ml
was aspirated and applied to an ELISA plate with preadsorbed anti-
DNA antibody. Sites of primary antibody binding were identified
using peroxidase-conjugated anti-BrdU antibody. A positive control
used purified human recombinant TNF-
 
a
 
 (TNF at 10 ng/ml; pro-
vided by Knoll Pharmaceuticals). Where indicated, ECs were incu-
bated with rEMAP II and/or exposed to hypoxia (pO
 
2
 
 
 
ø
 
 14 Torr)
using a specially constructed controlled environment chamber, as
described previously (11). In addition, the cleavage of the pro-
form of caspase-3 to the active 17-kD form was evaluated in
ECs exposed to rEMAP II to assess apoptosis. In brief, subcon-
fluent ECs were incubated with either vehicle or rEMAP II (1
 
m
 
g/ml) for 24 h at 37
 
8
 
C, and cells were lysed in the presence of
protease inhibitors. Equal amounts of protein were then subjected
 
to electrophoresis on a 12% SDS-PAGE gel, transferred to Im-
mobilon-P, blocked overnight in a casein-based blocking solu-
tion (Boehringer Mannheim), and probed with a polyclonal rabbit
anti–caspase-3 antibody (PharMingen). Specific binding was de-
tected using a chemiluminescence substrate (Pierce Chemical
Co.) and XAR-5 film (Eastman Kodak Co.).
 
Preparation of Recombinant Murine EMAP II, and Detection of
EMAP II Transcripts and Antigen.
 
rEMAP II was prepared from
 
Escherichia coli
 
 (host HMS174[DE3]) transformed with a plasmid
containing the coding sequence for mature EMAP II, as described
previously (6). Frozen (
 
2
 
80
 
8
 
C) 
 
E. coli
 
 cell paste was mixed 1:10
(wt/vol) with Tris-HCl (20 mM; pH 7.4) containing octyl-
 
b
 
-glucoside (0.1%), and a homogeneous suspension was formed
by agitation using a microfluidizer for 20 min (speed 60) at 4
 
8
 
C.
Polyethylenimine at pH 7 was then added to the homogenate to
a concentration of 0.25%, solids were removed by centrifugation
(5,000 
 
g
 
; 30 min), and the supernatant was retained. After filtra-
tion (0.2 
 
m
 
m), the sample was applied (3 ml sample/ml of gel) to
heparin Sepharose CL-4B (Amersham Pharmacia Biotech; 120 ml
bed volume) equilibrated in Tris-HCl (20 mM; pH 7.4) contain-
ing octyl-
 
b
 
-glucoside (0.1%), and the column was eluted with a
linear ascending NaCl gradient. Fractions were pooled on the
basis of purity by silver-stained SDS-PAGE, by immunoblotting
with antibodies prepared to the NH
 
2
 
 terminus of mature EMAP
II, and by biological activity measured in a tissue factor induction
assay (6). The heparin Sepharose pool was concentrated using an
Amicon Stirred Cell, and the retentate was desalted into 3-(mor-
pholino)-propane-sulfonic acid (Mops, 25 mM; pH 6.9) and then
applied to an SP Sepharose High Performance cation exchange
column (55 ml bed volume; Amersham Pharmacia Biotech). The
column was eluted by application of a 0–0.5 M ascending linear
salt gradient in Mops, and EMAP II–containing fractions were ad-
justed to 2 M in (NH
 
4
 
)
 
2
 
SO
 
4
 
, then applied to a phenyl-Toyopearl
650 M (Tosohaas) column (90 ml bed volume), equilibrated in
sodium phosphate (20 mM; pH 7) containing 1 M (NH
 
4
 
)
 
2
 
SO
 
4
 
.
The column was eluted with a descending salt gradient (2–0 M)
in sodium phosphate (20 mM), and EMAP II in the phenyl-Toyo-
pearl column eluate was concentrated to 3–5 mg/ml and formu-
lated into PBS (pH 7.4) by buffer exchange on a Sephadex G25
column (as above). LPS was removed using filtration through a
Posidyne filter (Pall Corp.), and LPS levels were estimated using
the Endospecy chromogenic assay (limit of detection 
 
,
 
10 pg/ml).
Purified EMAP II was subjected to NH
 
2
 
-terminal sequence anal-
ysis, mass spectrometry, and SDS-PAGE; the current material was
found to be homogeneous according to these criteria. The phenyl-
Toyopearl column and Posidyne filtration steps appeared to remove
certain toxic contaminant(s) associated with rEMAP II prepared by
preparative electrophoresis in previous studies (6). Purified rEMAP II
preparations (at a concentration of 1 mg/ml or more) were imme-
diately aliquoted and frozen at 
 
2
 
80
 
8
 
C in the presence of mouse
serum albumin at a concentration of 1 mg/ml (Sigma Chemical
Co.). When an aliquot of rEMAP II was thawed, it was used im-
mediately for experiments (it was not refrozen and used in future
studies). These procedures were essential to maintain the bioactiv-
ity of rEMAP II.
Antibody to rEMAP II was prepared by standard methods in
rabbits (12) and was found to be monospecific, based on immu-
noblotting of plasma and cell extracts, and that anti-EMAP II IgG
blocked the activity of rEMAP II in cell culture assays (6). This
antibody was used to develop an ELISA to detect EMAP II anti-
gen by the general protocol described previously (6).
Reverse transcription (RT)-PCR analysis for EMAP II tran-
scripts employed RNA extracted from murine tissues (BALB/c 
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mice) using the RNA Stat-60 kit (Tel-test, Inc.) according to the
manufacturer’s instructions, and reverse transcribed (1 
 
m
 
g) using
Taq polymerase (Perkin-Elmer Cetus). Primers were used for
EMAP II (primer 1, GCATCGCGTCTGGATCTTCGAATT;
and primer 2, GTATGTGGCCACACACTCAGCATT) and
 
b
 
-actin (GIBCO BRL). Thermocycling parameters for the ex-
periment shown in Fig. 2 A were as follows: 94
 
8
 
C for 30 s; 55
 
8
 
C
for 30 s; and 72
 
8
 
C for 30 s, for a total of 35 cycles. Samples were
subjected to agarose gel (1%) electrophoresis, and bands were vi-
sualized by ethidium bromide staining. Identity of amplicons was
confirmed by Southern blotting with the appropriate cDNA probes.
Two negative controls used in PCR experiments included a mi-
nus RT control, and a control in which the only DNA present
was that from an irrelevant plasmid, the receptor for advanced
glycation endproducts (13).
 
Matrigel and Corneal Neovascularization Models.
 
Matrigel (14, 15;
Collaborative Research) containing either vehicle (1% BSA);
rEMAP II (100 ng/ml) plus vehicle; basic fibroblast growth factor
(bFGF, 100 ng/ml; Collaborative Research) plus heparin (40 U/ml;
Sigma Chemical Co.) plus vehicle; rEMAP II (100 ng/ml) plus
bFGF/heparin plus vehicle; or heat-inactivated rEMAP II (100
ng/ml; alone or with bFGF/heparin) plus vehicle was mixed at
4
 
8
 
C. Matrigel mixtures were injected subcutaneously into
C57BL6/J mice (0.25 ml/site) at two sites per animal. In other
experiments, rEMAP II was not added to the Matrigel, but was
administered intraperitoneally, either active EMAP II (1 
 
m
 
g every
12 h), heat-inactivated EMAP II (1 
 
m
 
g every 12 h), or vehicle
alone, for a total of 14 d. The angiogenic response was analyzed
at 14 d after inoculation by routine histology and hemoglobin as-
say (Sigma Chemical Co.). The number of vessels in 10 high
power fields was determined per implant and is expressed as the
mean 
 
6 
 
SE in each experimental group.
The murine corneal neovascularization model followed the
general protocol of Kenyon et al. (16). Pellets for insertion into
the cornea were made by combining bFGF (20 mg; Intergen),
sucralfate (10 mg; Bukh Meditec), and Hydron polymer in etha-
nol (0.01 ml of a 12% solution; Interferon Sciences), and applying
the mixture to a 15 
 
3 
 
15 mm piece of synthetic mesh (Tetko).
The mixture was allowed to air dry, and fibers of the mesh were
pulled apart, yielding pellets containing 80–100 ng of bFGF. Pel-
lets containing bFGF were inserted into corneal pockets created 1
mm from the limbus at the lateral canthus of the eye. Mice were
then treated with vehicle or EMAP II (1 
 
m
 
g every 12 h) for the
next 5 d. After this period, eyes were evaluated for corneal
neovascularization; the number of vessels originating in the lim-
bus was counted over the entire orbit, and the area of neovascular
response was calculated according to the formula for an ellipse,
where 
 
A
 
 5 
 
[(clock hours) 
 
3
 
 0.4 
 
3
 
 (vessel length in mm) 
 
3
 
 
 
p
 
]/2.
Each clock hour is equal to 30
 
8
 
 at the circumference.
 
Murine Clearance Studies.
 
Clearance of EMAP II in mice was
assessed using 
 
125
 
I-labeled rEMAP II. rEMAP II was radioiodi-
nated by the Bolton and Hunter method (3.2 mol of ester/mol of
protein [17]), and the tracer was 
 
.
 
99% precipitable in TCA
(20%), migrated as a single 
 
ø
 
20-kD band on SDS-PAGE, and
had a specific radioactivity of 
 
ø
 
8,000 cpm/ng. BALB/c mice re-
ceived 
 
125
 
I-rEMAP II (0.26 
 
m
 
g) either intravenously via the tail
vein or intraperitoneally. Plasma samples were taken, and animals
were killed at 24 h. Plasma 
 
125
 
I-rEMAP II concentration data
were fit to a two-compartment open model using nonlinear re-
gression by extended least squares analysis (Siphar; SIMED). To
assess the “goodness of fit,” residual analysis (an examination of
the SD) was performed (18).
 
Murine Tumor Models.
 
For producing primary tumors to test
the effects of EMAP II treatment, LLC cells were rinsed with
HBSS, trypsinized, counted, resuspended in PBS, and injected
subcutaneously into backs of C57BL6/J mice (2 
 
3 
 
10
 
6
 
 cells/ani-
mal). On the third day after administration of tumor cells, the tu-
mor was reproducibly measurable, and this tumor volume was
taken for comparison with later measurements of the same tumor.
Animals then underwent intraperitoneal injection every 12 h for
12 d of either vehicle alone (serum albumin, 1%), vehicle plus
rEMAP II (at 100 or 1,000 ng), or vehicle plus heat-inactivated
rEMAP II (1,000 ng). Tumor growth was assessed with calipers
every third day (from days 3–15), and tumor volume was calcu-
lated according to the formula for a spherical segment (19), 
 
V
 
 5
p
 
h
 
(
 
h
 
2 
 
1 
 
3
 
a
 
2
 
)/6, where 
 
h
 
 5 
 
height of the segment, 
 
a
 
 5 
 
(length 
 
1
 
width)/2, and 
 
V
 
 5 
 
volume (each tumor was compared with itself
over multiple measurements, and change in volume was noted).
Tumor volume data were analyzed using the Kruskal-Wallis one-
way analysis of variance (ANOVA) and a Mann-Whitney mean
rank test. Data are expressed as a dimensionless ratio of observed
tumor volume divided by initial (day 3) tumor volume. Animals
were killed and tumors analyzed histologically at day 15. For pri-
mary tumors derived from an estrogen-independent breast carci-
noma, MDA-MB 468 cells (2 
 
3 
 
10
 
6
 
/animal) were injected sub-
cutaneously into nude mice (NCR Nude from Taconic Farms).
On the third day after injection of tumor cells, the tumor was
measured, and this tumor volume was used for comparison with
later measurements of that tumor as above. Animals underwent
intraperitoneal injection every 12 h for 69 d of either vehicle
alone (as above), vehicle plus rEMAP II (at 100, 1,000, or 10,000
ng), or vehicle plus heat-inactivated rEMAP II (10,000 ng). Tu-
mor growth was determined every sixth day, and tumor volume
was analyzed as above.
For the metastatic tumor model
 
 
 
(20, 21), C57BL6/J mice re-
ceived LLC cells subcutaneously and were observed until tumor
volume reached 
 
$
 
1.5 cm
 
3
 
. Animals then received rEMAP II
(1,000 ng/dose) in vehicle or vehicle alone intraperitoneally ev-
ery 12 h for 72 h before resection of the primary tumor. After
complete resection of the tumor (with no recurrence), mice were
observed for an additional 15 d, during which time they received
rEMAP II (1,000 ng i.p. every 12 h) in vehicle or vehicle alone
(same schedule). On day 15, lungs were injected intratracheally
with India ink (15%) to visualize lung surface nodules, and tissue
was fixed in Fekete’s solution (70% alcohol, 5% glacial acetic acid,
3.7% formaldehyde). Surface metastatic lesions were counted by
gross inspection of the tissue under 4
 
3
 
 magnification, and macro-
metastases were defined based on a smallest surface nodule diam-
eter 
 
.
 
2 mm.
 
Tissue Analysis: Histology, Apoptosis, and Immunohistology.
 
Histo-
logic analysis was performed on formalin-fixed, paraffin-embed-
ded tissue, using hematoxylin and eosin staining. The terminal
deoxynucleotidyl transferase–mediated dUTP-biotin nick end la-
beling (TUNEL) assay was used to evaluate apoptosis using the In
Situ Cell Death Detection kit (alkaline phosphatase detection system
from Boehringer Mannheim). Paraffin-embedded tissue was depar-
affinized, rehydrated, and incubated with proteinase K (1 
 
mg/ml)
for 30 min. After rinsing with PBS, slides were incubated with
TUNEL reaction mixture for 10 min, after which they were ex-
posed to Converter-AP. Alkaline phosphatase was revealed by in-
cubation with substrate (nitroblue tetrazolium [NBT]). For im-
munolocalization of EMAP II and CD31 antigens, we used rabbit
anti-rEMAP II IgG (5 mg/ml) and rat anti–murine CD31 anti-
body (4 mg/ml; PharMingen). Note that for staining of Matrigel
implants for CD31, rabbit polyclonal anti-CD31 IgG (1 mg/ml;
provided by Dr. Beat A. Imhof, Basel Institute of Immunology,344 Antiangiogenesis and EMAP II
Basel, Switzerland) was used. Tissues, fixed as above, were depar-
affinized, and underwent peroxide quenching. Using a histostain
kit from Zymed Laboratories, after blocking, sections were ex-
posed to anti-CD31 or anti–EMAP II IgG overnight at 48C. Sec-
tions were then incubated with secondary biotinylated antibody
as per the manufacturer’s protocol. A brief incubation with the
Streptavidin-HRP conjugate system (Zymed Laboratories) was
followed by development using the chromagen substrate amino-
ethylcarbazole. Sections were then counterstained with hematox-
ylin and mounted as indicated.
Results
Distribution of EMAP II in Normal Mice. EMAP II tran-
scripts were demonstrated in a range of organs (brain, liver,
lung, spleen, heart, kidney, and smooth muscle; Fig. 1 A),
though their levels appeared to be low, requiring PCR am-
plification to visualize the appropriate size amplicon. Nega-
tive controls for PCR amplification of EMAP II transcripts,
in which reverse transcriptase was omitted or tissue RNA
was replaced with an irrelevant cDNA, demonstrated no
band (Fig. 1 A, two far right lanes). Expression of EMAP II
transcripts was unaffected by infusion of LPS (100 mg/ani-
mal) or induction of hind limb ischemia (data not shown).
ELISA for EMAP II antigen showed virtually undetectable
levels in the above normal tissues (limit of detection ,250
pg/ml) and no peak of EMAP II in the plasma after LPS
administration or hind limb ischemia. These data indicated
that EMAP II is expressed only at the lowest levels in nor-
mal mice, and that it is unlikely to be an early mediator of
the host response to acute stimuli such as LPS or ischemia.
This clearly contrasts with the rapid production and signifi-
cant roles for proinflammatory cytokines such as IL-1 and
TNF in the acute response to tissue injury (2, 7, 8).
Preparative Scale Purification of rEMAP II. To further study
the effects of EMAP II in vitro and in vivo, it was important
to develop a preparative scale purification procedure. Previ-
ously, we used material eluted from SDS-PAGE correspond-
ing to ø20,000 Mr. Although this material was highly puri-
fied, it was difficult to scale-up such a method, and the
biologic properties of the resulting EMAP II were somewhat
variable, probably due to differing degrees of denaturation/
renaturation during SDS-PAGE and gel elution. This led us
to develop an alternate purification strategy. rEMAP II was
expressed in E. coli (Fig. 1 B, lane 1), and purified by polyeth-
ylenimine precipitation, followed by sequential application
to heparin Sepharose, SP Sepharose, and phenyl-Toyopearl.
Posidyne filtration was then performed to remove LPS (levels
were ,10 pg at rEMAP II concentrations of 3–5 mg/ml).
Details of chromatographic steps are described in Materials
and Methods. The final formulated material was homoge-
neous on SDS-PAGE, migrating as a diffuse band at ø20 kD
(Fig. 1 B, lane 2). Mass spectrometry gave a measured mass
of 18,006, which is close to the expected mass of 17,970
(data not shown). NH2-terminal sequence analysis showed a
single sequence with a 100% match between purified murine
EMAP II and the published sequence (5, 6).
Effect of EMAP II on bFGF-induced Angiogenesis. To eval-
uate  the ability of EMAP II to regulate blood vessel forma-
tion in response to known growth factors, bFGF and hep-
arin were mixed with a gel of basement membrane proteins
produced by Engelbreth-Holm-Swarm tumor cells (Matri-
gel) to serve as a model angiogenic stimulus (14, 15). Sub-
cutaneous Matrigel implants in C57BL6/J mice were eval-
uated 14 d after inoculation for vessel formation, cellular
infiltration, and hemoglobin content. Histologic analysis of
the gel showed formation of vessels to be most pronounced
and comparable in implants from animals treated with either
bFGF/heparin plus vehicle (albumin; data not shown) or
bFGF/heparin plus heat-inactivated rEMAP II plus vehicle
(Fig. 2 A); higher magnification confirmed the presence of
neovessels in these implants (Fig. 2 C). This induction of
blood vessel formation is similar to that reported previously
with bFGF in this model (15). In contrast, in implants from
animals treated with bFGF/heparin plus active rEMAP II,
there was marked reduction of vessel ingrowth (Fig. 2, B
Figure 1. PCR analysis of EMAP II transcripts in
normal murine tissue (A) and SDS-PAGE of puri-
fied rEMAP II (B). (A) RNA was harvested from
normal murine tissues as indicated, and processed
for PCR as described in the text. The bands corre-
sponding to the amplicons for EMAP II (400 bp)
and b-actin (560 bp) are indicated by arrows. A
100-bp ladder was used as the standard in the far left
lane. Negative controls include a lane in which re-
verse transcriptase was omitted (Minus-RT) and an-
other lane in which irrelevant plasmid DNA
(RAGE; reference 13) was added in place of sample
DNA (two far right lanes). (B) E. coli homogenate
and purified rEMAP II were subjected to reduced
SDS-PAGE (10–20% Tricine gels; 10 mg/lane), and
protein was visualized by Coomassie blue. Lane 1,
E. coli homogenate after centrifugation (12,000 g);
lane 2, rEMAP II formulated into PBS. Migration
of simultaneously run molecular weight standards is
indicated in kD.345 Schwarz et al.
and D), i.e., little to no vessel formation (n 5 40; this ex-
periment was performed seven times). Vessel confirmation
was established by use of CD31 (Fig. 2 E, vehicle plus heat-
inactivated EMAP II plus bFGF; and Fig. 2 F, vehicle plus
EMAP II plus bFGF). Consistent with these histologic
findings, there was a 76% reduction in hemoglobin content
in corresponding implants containing bFGF/heparin plus
rEMAP II, compared with bFGF/heparin plus vehicle or
heat-inactivated EMAP II plus bFGF/heparin plus vehicle
(Fig. 2 H). Matrigel implants were scored for the mean
number of vessels per 10 high power fields. When rEMAP
II was present, vessel density was reduced (P , 0.0001 by
Kruskal-Wallis; Fig. 2 G), consistent with the results of the
hemoglobin assay. Further experiments were also done to
be certain that the observed effects in the Matrigel model
were not due to potentially toxic high local concentrations
of rEMAP II in the implant itself. For these studies, animals
received Matrigel implants containing bFGF/heparin, fol-
lowed by intraperitoneally administered rEMAP II (1 mg
every 12 h for 14 d), heat-inactivated rEMAP II (same
dose), or vehicle alone. Results were analogous to those
described above; treatment with rEMAP II suppressed vas-
cular ingrowth into the Matrigel, whereas heat-inactivated
EMAP II or vehicle alone had no effect (data not shown).
In view of our previous in vitro studies with EMAP II
(5, 6), in which it initially appeared to have properties of an
inflammatory mediator, the results of these experiments
in the Matrigel model were unexpected. This led us to
Figure 2. Matrigel angiogenesis model:
effect of rEMAP II on bFGF-induced
neovascularization. Mice received subcuta-
neous Matrigel implants and were killed af-
ter 14 d to analyze new vessel formation by
histologic examination and hemoglobin as-
say. (A, C, and E [arrows in C indicate ves-
sels denoted in E]) Implant containing
bFGF/heparin plus heat-inactivated rEMAP
II (100 ng/ml) plus vehicle. (B, D, and F
[arrows in D indicate vessels seen in F])
Implant containing bFGF/heparin plus
rEMAP II (100 ng/ml) plus vehicle. (G)
The density of vessels in Matrigel implants,
under the conditions described above (A–
F), was determined by counting 10 high
power fields (HPF) of sections stained with
anti-CD31 antibody (mean 6 SE is shown).
(H) Results of hemoglobin assay (reported
as percentage of control; Matrigel with ve-
hicle arbitrarily defined as 100%). Note that
the bar designated bFGF refers to implants
containing bFGF/heparin alone. Results
were evaluated by Student’s t test; P ,
0.001 comparing hemoglobin levels in the
presence of rEMAP II with control and
bFGF groups. There is a statistically signifi-
cant decrease in vessel counts in Matrigel
implants containing EMAP II compared
with control or those containing heat-inac-
tivated EMAP II (*P , 0.0001 by Kruskal-
Wallis). These experiments were repeated
seven times. Original magnifications: A and
B, 87.53; C and D, 2003; E and F, 4003.346 Antiangiogenesis and EMAP II
confirm these observations in another neovascularization
model, namely that using the mouse cornea (16). For these
studies, bFGF was incorporated into slow-release polymer
pellets (Hydron) which were implanted into corneal pock-
ets of mice. Animals then received rEMAP II (2 mg/d ev-
ery 24 h) or vehicle alone intraperitoneally for 5 d. Corneal
neovascularization was evident in animals receiving vehicle
(Fig. 3 A), and was markedly suppressed by treatment with
rEMAP II (Fig. 3 B). This initial impression was confirmed
by counting the number of neovessels originating in the
limbus (Fig. 3 C) and by determining the area of corneal
neovascularization (Fig. 3 D); in each case, ø60% suppres-
sion of vessel ingrowth was observed. Taken together, these
data in the Matrigel implant and corneal neovascularization
models suggested that rEMAP II had the capacity to sup-
press neovessel formation in response to bFGF.
Plasma Clearance and Tissue Deposition of Infused rEMAP II.
To perform further in vivo studies with rEMAP II, its plasma
clearance was evaluated. Clearance studies were performed
using either intravenously or intraperitoneally administered
125I-rEMAP II (Fig. 4). The fall in plasma concentration of
125I-rEMAP II after intravenous injection best fit a biex-
ponential function (18); the distribution and elimination
half-lives were 0.47 6 0.17 and 103 6 5 min, respectively.
After intraperitoneal injection, 125I-EMAP II was detected
in plasma after 1 min, and the maximum concentration was
reached by 35 6 10 min. The resorption phase of rEMAP II
handling in vivo was best described as a first-order process.
The elimination phase after intraperitoneal administration
fit to a monoexponential decline, and the resorption and
elimination half-lives were 50.1 6 0.1 and 102 6 6 min,
respectively.
Figure 3. Corneal neoangio-
genesis model: effect of rEMAP
II on bFGF-induced neovascular-
ization. Hydron pellets contain-
ing bFGF (ø90 ng) were im-
planted in corneal pockets. Mice
were then treated with EMAP II
(2 mg i.p. every 24 h for 5 d; B) or
vehicle (A), and the corneal neo-
vascular response was assessed.
The total number of neovessels
originating in the limbus was
counted (C; *P , 0.003), and the
area of neovascularization was cal-
culated (D; *P , 0.002). Data
shown are the results of 16 obser-
vations in 8 animals in each of the
experimental groups, for a total of
32 observations in 16 animals. The
experiment was repeated twice.
Figure 4. Disappearance of 125I-EMAP II from mouse plasma after in-
travenous (u) or intraperitoneal (j) infusion. Mice received 125I-EMAP
II (0.26 mg/ml) by either intravenous or intraperitoneal injection, and
plasma was sampled at the indicated time points. The method for data fit-
ting and parameters of clearance are described in the text.347 Schwarz et al.
Effect of rEMAP II on Growth of Primary and Metastatic
Tumors. Mice implanted subcutaneously with LLC cells
developed tumors which were first measured when they
achieved a volume of z9–10 mm3, ø3 d after inoculation
of cells. The volume of each tumor was then measured every
third day and compared with the initial volume of that tumor
on day 3. Compared with tumor-bearing animals treated
with vehicle alone or vehicle plus heat-inactivated EMAP
II, mice receiving active rEMAP II showed a striking re-
duction in tumor volume (Fig. 5 A). Differences between
tumor volume in control and EMAP II–treated animals
were statistically significant using either the Kruskal-Wallis
one-way ANOVA (P , 0.034) or comparing control ver-
sus high dose rEMAP II by Mann-Whitney analysis (P ,
0.003). Histologic study of LLC tumors allowed to grow
for 15 d and injected intraperitoneally every 12 h with ve-
hicle (albumin, 1%) demonstrated a densely packed and uni-
form cell population (Fig. 5 B). Tumors from animals receiv-
ing heat-inactivated rEMAP II (at 1,000 ng/dose) were similar
in appearance to vehicle controls (data not shown). After
administration of rEMAP II at 1,000 ng/dose twice daily
for 12 d, areas of pyknosis were observed in the tumor bed
(Fig. 5 D). At higher magnification, rEMAP II–induced ar-
eas of pyknosis had a general perivascular distribution (Fig.
5 D, inset). In Fig. 5, D, E, and F, the close association of
pyknotic areas in the tumor (D), localization of the vascular
marker CD31 (F), and evidence of DNA fragmentation us-
ing the TUNEL assay (E) are observed (through the use of
sequential sections). There were no such apoptotic areas in
control tumors treated with vehicle alone (Fig. 5 C). There
was a dose-dependent increase in apoptotic areas present in
the tumors with 100 and 1,000 ng of EMAP II. Mice treated
with rEMAP II were normally active, continued food/water
consumption, and maintained their weight comparably to
control mice.
To determine whether the tumor-suppressive effect of
rEMAP II could be extended to human tumors, the
MDA-MB 468 cell line, derived from an estrogen-indepen-
dent breast carcinoma (HTB 132) was used to establish sub-
cutaneous tumors in nude mice. Mice were treated with ei-
ther of three doses of rEMAP II (100, 1,000, or 10,000 ng/
12 h i.p.), heat-inactivated rEMAP II (10,000 ng/12 h i.p.),
or vehicle alone for 69 d after the same protocol as for the
LLC tumors (Fig. 6, A and B). A concentration-dependent
inhibition of tumor volume was observed in the presence
of rEMAP II that was most striking and reached a plateau at
the two higher doses (1,000 and 10,000 ng; P , 0.01 by
Mann-Whitney and P , 0.001 by Kruskal-Wallis). There
was no evidence of toxicity over the almost 10-wk period
of rEMAP II administration.
Figure 5. Effect of rEMAP II on primary LLCs. Mice were injected
subcutaneously on day 1 with LLC cells, and then on days 3–15 were
treated intraperitoneally every 12 h with either vehicle alone (control),
rEMAP II (100 or 1,000 ng), or heat-inactivated rEMAP II (1,000 ng).
(A) Change in tumor volume in each of the four groups (mean 6 SE) is
shown (n 5 40), and data analysis was performed as described in the text
(**: P , 0.034, Kruskal-Wallis; and P , 0.003, Mann-Whitney). The
volume of tumor (in mm3) on day 3 was as follows: control group, 10.2
6 2.3 (mean 6 SD); rEMAP II–treated (100 ng) group, 9.8 6 2.6;
rEMAP II–treated (1,000 ng) group, 10.3 6 2.2; heat-inactivated rEMAP
II group, 9.2 6 2.8. Data are expressed as a dimensionless ratio of tumor
volume on day 15 to that on day 3 (each animal compared only with it-
self). (B–F) Representative sections of LLC tumors harvested from mice
treated with vehicle alone (B and C) or rEMAP II (1,000 ng; D–F) on
day 15. In F (arrow indicates the area of inset at higher magnification), the
association of pyknotic areas observed in D (arrow indicates the area of
inset at higher magnification) with sites of microvessels was confirmed by
staining sequential sections with anti-CD31 IgG. In E (arrow indicates
the area of inset at higher magnification), TUNEL staining of adjacent
sections demonstrates apoptotic nuclei in the region with multiple mi-
crovessels. These results in rEMAP II–treated tumors contrast with the
uniform appearance of untreated tumors (B and C) and their lack of apop-
totic areas after TUNEL staining of sections (C). These experiments were
repeated three times. Original magnifications: B–F, 87.53; D–F insets,
4003.348 Antiangiogenesis and EMAP II
As established metastatic foci require blood vessel in-
growth to expand beyond 1–2 mm (22–25), we reasoned
that rEMAP II might suppress growth of metastatic lesions.
The LLC model was used by allowing primary tumors to
grow to a volume of $1.5 cm3, at which time metastases
are present (but suppressed by the primary tumor [19, 20]).
Then, the primary lesion was resected (with no recurrence at
the site of resection), and analysis of surface lung nodules was
undertaken 15 d later. rEMAP II treatment was begun 72 h
before resection of the primary tumor and continued through
the end of the experiment. Animals receiving rEMAP II
(1,000 ng i.p. every 12 h; Fig. 7, B and D, arrow indicates
area of inset) showed significantly fewer and smaller surface
nodules, compared with vehicle (Fig. 7, A and C) by gross
inspection and histologic study. Consistent with these data,
rEMAP II–treated animals demonstrated 65% suppression
(P , 0.009 by Mann-Whitney) in outgrowth of the total
number of surface metastases, compared with mice receiving
vehicle alone (Fig. 7 E). Of the 35% of metastases present in
rEMAP II–treated animals, ø80% of these metastases were
inhibited, such that the maximum diameter was ,2 mm
(i.e., predominately micrometastases were present) compared
with controls (P , 0.002 by Student’s t test; Fig. 7 E, inset).
Effect of rEMAP II on Endothelium. Our data thus far
demonstrated an association of EMAP II with induction of
apoptosis in tumors, the latter at least in part in a perivascu-
lar distribution. These data suggested the possibility that tu-
mor vasculature might be a target of EMAP II. ELISA for
DNA fragmentation was performed to more precisely de-
lineate apoptotic effects of rEMAP II on growing cultured
endothelium. There was a dose-dependent increase in DNA
fragmentation in cultured bovine capillary endothelium,
reaching 250% over that observed in controls within 24 h
(Fig. 8 A). As tumor tissue is also known for the presence
of areas of local tissue hypoxia/hypoxemia (26, 27), we as-
sessed whether rEMAP II might display enhanced activity
under oxygen deprivation. When cultured subconfluent
capillary ECs were exposed to hypoxia (pO2 ø 14 Torr),
DNA fragmentation was accelerated, reaching a level of
250% above that observed with vehicle alone within 12 h
(rather than the 24 h required for an effect of this magni-
tude in normoxia; Fig. 8 A). This was consistent with the
accelerated appearance of apoptotic bodies by 6-diamidine-
2-phenylindoledilactate (DAP-1) staining of hypoxic cultured
capillary endothelial cultures exposed to rEMAP II. Con-
trols in which bovine capillary ECs were treated with heat-
inactivated rEMAP II, in place of active rEMAP II, showed
no induction of apoptosis (data not shown). Induction of
apoptosis after exposure to rEMAP II was not as striking
in cultured bovine aortic or human umbilical venous ECs,
where a maximum of ø50% apoptosis over untreated con-
trols was observed at the highest concentrations of rEMAP
II tested (Fig. 8 B; analysis by Student’s t test showed no
statistical significance). In contrast, LLC or MDA-MB 468
cells, and nontransformed vascular SMCs demonstrated no
increase in DNA fragmentation after exposure to rEMAP
II under the conditions above by ELISA (Fig. 8 C) or
DAP-1 staining (data not shown). Consistent with the ob-
served induction of apoptosis in ECs, we noted that
rEMAP II induced activation of the cytosolic protease
caspase-3 to its active 17-kD form found in cells undergo-
ing apoptosis (Fig. 8 D).
Discussion
Neovascularization is a critical regulator of the growth of
both primary and metastatic neoplasms (22–25). Earlier studies
called attention to the role of angiogenic factors, such as vascu-
lar endothelial growth factor (VEGF [28–30]), acidic FGF
(31), bFGF (32), and angiogenin (33–35), in promoting tumor
Figure 6. Effect of rEMAP II on tumors derived from MDA-MB 468
cells. Nude mice were injected subcutaneously on day 1 with MDA-MB
468 cells, and then on days 3–69 were treated intraperitoneally every 12 h
with either vehicle alone (Control), rEMAP II (100, 1,000, or 10,000 ng),
or heat-inactivated rEMAP II (10,000 ng). Change in tumor volume in
each of the five groups (mean 6 SE) is shown (n 5 50), and data analysis
was performed as described in the text (P , 0.005 by Mann-Whitney,
and P , 0.001 by Kruskal-Wallis compared with controls). The volume
of tumor (in mm3) on day 3 was as follows: control group, 2.9 6 1.3
(mean 6 SD); rEMAP II–treated (100 ng) group, 2.5 6 1; rEMAP II–
treated (1,000 ng) group, 4.4 6 1.2; rEMAP II–treated (10,000 ng)
group, 4.4 6 1.2 (A); rEMAP II–treated (10,000 ng) group, 3.5 6 1.3;
heat-inactivated rEMAP II group, 2.6 6 1.1 (B). Data are expressed as a
dimensionless ratio of tumor volume on the indicated day compared with
day 3 (each animal compared only with itself). These experiments were
repeated three times.349 Schwarz et al.
growth and establishing metastases. For example, in a trans-
genic murine model, a switch in phenotype from benign fi-
broma to malignant fibrosarcoma was closely tied to expres-
sion of angiogenic mediators (36), and antibody to VEGF
inhibited growth of explanted human tumors in athymic mice
(29, 30). Similar inhibition of experimental tumor growth has
also been observed with antibodies to angiogenin (35) and
bFGF (37). Alternatively, recent work has identified endoge-
nous peptides with antiangiogenic activities, including an-
giostatin (20), thrombospondin (38), and glioma-derived an-
giogenesis inhibitory factor (39). They can inhibit tumor
growth either at the primary tumor site (thrombospondin
[38]) or at a site of distant metastases (angiostatin [20, 40]).
Formation of the tumor vascular bed, as well as blood vessel
formation in other situations, such as in ischemia, wound heal-
ing, and atherosclerosis (41–44), is presumably also controlled
by the interaction of such positive and negative stimuli on en-
dothelium in diverse vascular beds.
Carcinogen-induced murine meth A and similar tumors
(1, 2) are ideally suited to the analysis of host–tumor inter-
actions because short-term vascular insufficiency (exagger-
ated by concomitant administration of an agent such as TNF)
and longer-term immunologic mechanisms limit local tu-
mor growth (1, 2, 45–48). In fact, acute local (intratumor)
administration of EMAP II to meth A tumors resulted in
thrombohemorrhage in the tumor bed (6), a finding quite
distinct from what we observed in the current study in which
EMAP II was administered systemically at lower doses over
longer time periods. Consistent with the ability of EMAP II
to modulate vessel integrity was the observation that neoves-
sel formation into bFGF-containing implants was blocked
by rEMAP II. In contrast to these results with rEMAP II,
other cytokines such as TGF-b or TNF-a have been found
to induce vascular ingrowth in angiogenesis models (49–51).
In the LLC model, rEMAP II attenuated growth of pri-
mary tumors and resulted in a histologic picture of apop-
totic tissue injury, at least in part in a perivascular distribu-
tion, which progressed to nonviable tumor, probably as a
result of severe ischemia. The observation that apoptosis in
EMAP II–treated tumors extended beyond the vasculature
raises the possibility of a paracrine effect whereby results of
EC–EMAP II action might cause release of factors toxic to
nearby cells. In support of the suggestion that EMAP II was
initially targeting the vasculature, we found that rEMAP II
also markedly attenuated growth of a human breast carci-
noma line (MDA-MB 468) grown in nude mice. The find-
ing that EMAP II diminished lung surface metastases, and,
especially, macrometastases, is also consistent with the con-
cept that neovasculature feeding the tumor, as well as in the
tumor, is a target of EMAP II. It is notable that despite a
Figure 7. Lung metastasis model with LLC. Mice received LLC cells subcutaneously and were observed until tumors reached a volume of $1.5 cm3,
at which time animals were treated with rEMAP II (1,000 ng i.p. every 12 h; n 5 8) or vehicle alone (control; n 5 6) for 72 h. Tumors were subse-
quently resected (there were no local recurrences), and the same treatment regimen was continued for the duration of the study, an additional 15 d. India
ink was instilled intratracheally to enhance visualization of metastases (pale areas) compared with normal tissue (dark areas). Gross appearance of lungs
demonstrated many surface macrometastases in controls (A) versus their marked suppression in rEMAP II–treated mice (B). Histologic examination con-
firmed this impression (C, vehicle-treated; D, EMAP II–treated; arrow in D and inset in D indicate the presence of micrometastasis). (E) Surface lung
metastasis/nodule data from all animals were analyzed using Mann-Whitney (*P , 0.009). Total surface metastases are shown in the main figure (mean 6
SE), and surface macrometastases (.2 mm; mean 6 SE for control and EMAP II–treated groups were 80 6 12.5 and 20 6 13%, respectively), counted
using a calibrated ocular, are shown in the inset (by Student’s t test, P , 0.002). These experiments were repeated four times. Bar (A and B): 1 cm; orig-
inal magnifications: C and D, 87.53; D inset, 2003.350 Antiangiogenesis and EMAP II
prolonged course of rEMAP II treatment, ø10 wk, no un-
toward effects on general health of the animals was ob-
served, and pathologic analysis of normal organs revealed
no lesions. This suggested that actions of EMAP II were lo-
calized, under these conditions, to the tumor. However,
our data do not rule out the possibility that EMAP II may
have other effects on the tumor beyond that on the vascu-
lature. For example, the action of EMAP II on endothe-
lium or other elements in the tumor microenvironment
might release diffusible mediators toxic for tumor cells, thus
causing tumor injury initially close to the vasculature, but
then extending deeper into the tumor.
A salient feature of tumor vasculature, which distinguishes
vessels in the tumor stroma from those in normal tissue, is
the increased fraction of growing/migrating ECs (22–24).
Our studies in cell culture suggested an effect of rEMAP II
focused on growing capillary endothelium, predominately
induction of apoptosis, supported by our observation that
there was activation of caspase-3, a key protease that is trig-
gered during the early stages of apoptosis. In contrast, bovine
aortic and venous endothelium was less susceptible to the ef-
fects of EMAP II. Furthermore, addition of the cytokine to
cultures of growing tumor cells (LLC or MDA-MB 468)
showed no change in cell proliferation or induction of apop-
tosis, though rEMAP II suppressed these tumors in vivo. En-
hanced EMAP II–induced apoptosis in hypoxic endothelial
cultures provided further support for the relevance of our
finding to tumor biology, as the presence of hypoxic areas in
tumors is well established (26, 27). On a cellular level, hy-
poxia could potentially sensitize endothelium to EMAP II by
several mechanisms, including arrest of cells at the G1/S in-
terface (11) or increased sensitivity to subsequent encounters
with oxidizing stimuli. In support of the latter hypothesis, pi-
lot studies suggest that EMAP II has an important effect on
cellular redox status, as addition of N-acetylcysteine blocks
EMAP II–mediated endothelial apoptosis. Analysis of mech-
anisms through which EMAP II induces possible cellular ox-
idant stress, further definition of the caspase pathway, and
Figure 8. Effect of EMAP II on cultured ECs. (A) DNA fragmentation by ELISA of subconfluent cultured bovine capillary ECs in normoxia or hy-
poxia (pO2 ø 14 Torr), exposed to rEMAP II as indicated or heat-inactivated EMAP II (data not shown). (B) The same experiments were performed
with subconfluent bovine aortic and venous ECs. (C) The ELISA for DNA fragmentation was performed on LLC, MDA-MB 468, meth A, or vascular
SMCs after 24 h of exposure to EMAP II. Data shown represent mean and, in each case, SE was ,10%. Experiments with bovine capillary ECs and bo-
vine aortic/venous ECs were repeated three and two times, respectively. (D) ECs exposed to rEMAP II had activation of caspase-3 (lane 2) found in cells
undergoing apoptosis compared with control (lane 1).351 Schwarz et al.
elucidation of the cell surface receptor for EMAP II will pro-
vide more definitive answers to questions concerning the
specificity and selectivity of its cellular effects.
The striking feature of our in vivo studies is the suppres-
sive effect of rEMAP II on tumors without, apparently, an
adverse affect on the function of normal organs. We sug-
gest that this is due to EMAP II’s effect on the endothe-
lium; EMAP II could perturb endothelium in vivo not
only by direct effects on endothelial apoptosis, but also by
other means. For example, EMAP II–mediated induction
of endothelial tissue factor could trigger local activation of
clotting in the tumor bed, thereby diminishing blood flow
and enlarging the volume of tumor at risk for ischemia.
EMAP II might also modulate the expression of other me-
diators that control the local angiogenic balance, including
enhanced activity of pathways regulating production of an-
giostatic peptides, such as angiostatin or thrombospondin,
and/or might suppress expression of proangiogenic factors
in the tumor bed. Furthermore, EMAP II might elicit en-
dothelial production of mediators that directly impair tu-
mor cell viability (as mentioned above). Though there are
many mechanistic, physiologic, and practical questions to
be explored in future studies (e.g., whether EMAP II will
affect well-established vessels in human tumors that grow
over much longer time periods than the accelerated murine
models; or whether an optimal antitumor regimen of
EMAP II will induce tumor regression or just be static),
our data support the potential of EMAP II, a cytokine with
apparent antiangiogenic properties, to suppress primary and
metastatic tumor growth, and to induce apoptosis in the
tumor without apparent adverse affects on normal organs.
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